Brexpiprazole-Associated Pisa Syndrome (Pleurothotonus) in a Patient With Dementia. Issue 3 (14th May 2022)

• Record Type: Journal Article
• Authors: Nagai, Yasuhito; Yamazaki, Takahiro; Sugita, Tomoyuki; Shibata, Nobuto
• Is Part Of: Clinical neuropharmacology. Volume 45:Issue 3(2022)
• Page Start: 72
• Page End: 73
• Publication Date: 2022-05-14
• Subjects: brexpiprazole -- Pisa syndrome -- pleurothonus -- dystonia -- dementia; Neuropharmacology -- Periodicals; 615.78
• DOI: 10.1097/WNF.0000000000000500
• Languages: English
• ISSNs: 0362-5664

Abstract

Abstract : Objectives: The aims of the study were to report brexpiprazole-induced Pisa syndrome (PS) in a patient with Alzheimer disease and to discuss the pathophysiology and the treatment of PS. Methods: We report a 71-year-old female patient with Alzheimer disease. After 2 months medication of brexpiprazole, she presented PS. By switching to quetiapine, the symptom was ameliorated; however, transient acute dystonia was occurred. Conclusions: Drug-induced PS may be associated with dopamine-acetylcholine imbalance. This imbalance causes the dysfunction of the cortex and basal ganglia and the dysfunction of sensory and somatosensory system. Stopping the offending drugs is a choice for the treatment of PS. This is the first report of PS-induced brexpiprazole.